Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions
Uveal NeoplasmsMelanoma, Uveal
Interventions
BIOLOGICAL

Tumor Infiltrating Lymphocytes (TIL)

TIL infusion intravenously through a central vein catheter over 20-30 minutes. Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours beginning within 24 hours of TIL infusion and continuing for up to a maximum of 6 doses.

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
lead

Udai Kammula

OTHER